Clinical trial · Interventional
Individualized Chemotherapy Based on BRCA1 and RRM1 mRNA for Advanced Non-small Cell Lung Cancer (NSCLC)
Individualized 1st Line Chemotherapy Based on BRCA1 and RRM1 mRNA Expression Levels for Advanced Non-small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Gemcitabine, docetaxel, CPT-11 and cisplatin are effective in 1st line treatment of advanced non-small cell lung cancer (NSCLC). Platinum-based doublets including gemcitabine, docetaxel or CPT-11 are standard 1st regimens. BRCA1 and RRM1 expression levels are reported to be associated with sensitivity of the tumor cells to cytotoxic agents. Some Phase II or III trials did prove feasibility of customized chemotherapy based upon expression levels of one or two biomarkers in the NSCLC patients. The investigators think customized chemotherapy may further improve efficacy of chemotherapy in advanced NSCLC. But there is no randomised trial to compare efficacy of standard chemotherapy with individualized chemotherapy in this setting. So, the investigators plan to initiate this phase II trial to compare efficacy between standard chemotherapy of gemcitabine/cisplatin versus customized chemotherapy in chemonaive NSCLC patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| gemcitabine/cisplatin | Drug | — | UNRESOLVED |
| Gemcitabine, Docetaxel, CPT-11,Cisplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm 1
- description
- Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
- interventionNames
- Drug: Gemcitabine, Docetaxel, CPT-11,Cisplatin
- type
- ACTIVE_COMPARATOR
- label
- Arm 2
- description
- gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
- interventionNames
- Drug: gemcitabine/cisplatin
Primary outcomes (1)
- measure
- Overall response rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Written informed consent, 2. Histologically confirmed stage M1a or M1b NSCLC, 3. Aged over 18 years old, 4. Measurable disease, 5. Life expectancy of at least 12 weeks, 6. No prior chemotherapy or target therapy, 7. No brain metastases or spinal cord compression, 8. Less than 10% body weight loss, 9. ECOG performance status 0-2, 10. Adequate vital organ function (haematological, renal, hepatic, etc). 11. Enough tissue for detection of BRCA1 and RRM1 expression. Exclusion Criteria: 1. Prior systemic cytotoxic chemotherapy or EGFR TKI therapy, 2. Positive pregnancy test, 3. Another active malignancy, other than superficial basal cell and squamous cell or carcinoma in situ of the cervix, within the last 5 years, 4. Patients with brain metastases or spinal cord compression, 5. Allergy to gemcitabine, cisplatin, docetaxel, CPT-11, 6. Any unstable systemic disease including active infection, 7. No enough tissue for detection of BRCA1 and RRM1
References
Publications (0)
Data not yet available